Search
SPP 301
go.drugbank.com/drugs/DB05290InvestigationalThis study was designed to evaluate whether avosentan influences the pharmacokinetics of steroid oral contraceptives.
Mevidalen
go.drugbank.com/drugs/DB19034InvestigationalMevidalen is under investigation in clinical trial NCT03305809 (A Study of LY3154207 in Participants With Dementia Due to Lewy Body Dementia (LBD) Associated With Idiopathic Parkinson's Disease (PD) or
Radotermin
go.drugbank.com/drugs/DB19127InvestigationalRadotermin is under investigation in clinical trial NCT01182337 (A Clinical Trial to Evaluate the Safety, Tolerability and Preliminary Effectiveness of Single Administration Intradiscal Rhgdf-5 for the
Cenplacel-L
go.drugbank.com/drugs/DB19188InvestigationalCenplacel-L is under investigation in clinical trial (Study of Human Placenta-derived Cells (PDA001) to Evaluate the Safety and Effectiveness for Patients With Ischemic Stroke) for the treatment of patients
Serabelisib
go.drugbank.com/drugs/DB14935InvestigationalSerabelisib is under investigation in clinical trial NCT02625259 (A Study to Evaluate the Relative Bioavailability, Effect of Food, and Gastric Potential Hydrogen (pH) Modification on the Pharmacokinetics
Iopofosine I-131
go.drugbank.com/drugs/DB15244InvestigationalIopofosine I-131 (NM-404 I-131) is under investigation in clinical trial NCT01495663 (Dose Escalation Study of I-131-CLR1404 in Subjects With Cancer That Does Not Respond to Treatment or Has Returned).
Muplestim
go.drugbank.com/drugs/DB12431InvestigationalMuplestim is under investigation in clinical trial NCT00002258 (A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL
Azemiglitazone
go.drugbank.com/drugs/DB16028InvestigationalAzemiglitazone is under investigation in clinical trial NCT01280695 (A Randomized, Double-blind, Comparator- and Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability and Efficacy
BMN-351
go.drugbank.com/drugs/DB18186InvestigationalBMN-351 is a fully modified 18-mer oligonucleotide with a TEG modification at its 5' end that binds to exon 51 of dystrophin pre-mRNA.